FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB	APP	ROV	Ά
-----	-----	-----	---

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

transaction was made pursuant to a contract, instruction or written plan for the

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

purchase or sale issuer that is into	ended to satisfy the lase conditions of Rule instruction 10.			
	ess of Reporting Pers	on <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]	Relationship of Reporting Person(s) to Issuer     (Check all applicable)
ALSTODT I	<u>LANCE</u>		<u> </u>	X Director X 10% Owner
(Last)	(First)	(Middle)		X Officer (give title Other (specify below) below)
BIORESTORA	TIVE THERAPIE DRIVE, SUITE 1	` ,	3. Date of Earliest Transaction (Month/Day/Year) 10/06/2025	President, CEO, COB
(Street) MELVILLE	NY	11747	4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person
(City)	(State)	(Zip)		Form filed by More than One Reporting Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

in this of occurry (mounty)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Ad Disposed Of (D			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(1150.4)
Common Stock	10/06/2025		A		15,625	A	\$1.6	187,497	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (II 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$5.08							(1)	08/18/2031	Common Stock	293,479		293,479	D	
Stock Option	\$5.08							(1)	11/04/2031	Common Stock	42,059		42,059	D	
Stock Option	\$2.91							(2)	02/17/2033	Common Stock	106,762		106,762	D	
Stock Option	\$1.45							(3)	02/13/2034	Common Stock	438,596		438,596	D	
Stock Option	\$2.46							(4)	02/14/2035	Common Stock	791,885		791,885	D	
Warrant	\$2.75	10/06/2025		A		11,719		04/08/2026	10/08/2030	Common Stock	11,719	\$0	11,719	D	

### Explanation of Responses:

- 1. The option is currently exercisable.
- 2. The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
- 3. The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
- 4. The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.

/s/ Lance Alstodt

10/17/2025

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.